Pemazyre (Pemigatinib) Patent Expiration, LOE Window & CMS Spending
Pemazyre (Pemigatinib) by Incyte: FDA Orange Book core substance LOE 2040-10-03, 0 AB generics, $35.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Incyte |
| FDA Application & Pathway | N213736 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-10-03 |
| Last Listed Patent or Exclusivity Date | 2040-10-03 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $35.1M |
| 2024 Medicare Part D Spend | $29.5M |
| 2024 Medicaid Spend | $5.5M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 17.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.